Soluble mediator

US10328124B2 · kind B2 · utility

Assignee

• THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH · AU

Inventors

• Esther Bandala Sanchez · Melbourne, AU
• James Dromey · Melbourne, AU
• Leonard Charles Harrison · Melbourne, AU
• Yuxia Zhang · Baofeng County, CN

Key dates

• Filing date: May 9, 2018
• Grant date: Jun 25, 2019
• Expiry date: May 9, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.